Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003
Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003
复制标题
DOI：
10.1038/sj.bmt.1704743
复制
发表时间：
2005-02-01
影响因子：
4.8
通讯作者：
Grupp, SA
中科院分区：
文献类型：
--
作者：
Pulsipher, MA;Levine, JE;Grupp, SA
外周血干细胞（PBSC）在成人异体移植中的应用已大大增加。这一趋势也反映在儿科，健康儿童越来越多地通过单采捐献PBSC或供体淋巴细胞输注（DLI）供患病兄弟姐妹使用。有一个潜在的担忧，即收集PBSC的风险可能因儿童捐赠者而异。然而，目前还没有大型研究评估这一人群的安全性问题。为了满足这一需求，我们回顾了来自儿童血液和骨髓移植联盟22个机构的201名正常儿童献血者（8个月至17岁，中位数11.8岁）的218份献血者（213份PBSC， 5份DLI）。供体接受生长因子的中位数为4天，平均收集量为9.1 x 10(6)个CD34+细胞/kg受体体重。年龄越小、单采天数越长、男性越高，CD34+细胞/kg供体重量的产量越高。生长因子引起的疼痛是轻微的，不到15%的患者报告。大多数捐助者
The use of peripheral blood stem cells (PBSC) for allogeneic transplants in adults has greatly increased. This trend is reflected in pediatrics, where healthy children increasingly are donating PBSC or donor lymphocyte infusion (DLI) via apheresis for use by ill siblings. There is a potential concern that the risks of PBSC collection may differ for pediatric donors. However, no large studies have assessed safety issues in this population. To address this need, we reviewed 218 ( 213 PBSC, five DLI) collections in 201 normal pediatric donors ( 8 months to 17 years, median 11.8 years) at 22 institutions in the Pediatric Blood and Marrow Transplant Consortium. Donors received a median of 4 days of growth factor, and mean collection yield was 9.1 x 10(6) CD34+ cells/kg recipient weight. Younger age, days of apheresis, and male gender predicted increased yield of CD34+ cells/kg donor weight. Growth factor-induced pain was mild and reported in less than 15% of patients. Most donors